From "First Showcase" to "First Launch": Cutting-edge innovation moves faster toward real-world application
At the ninth CIIE, more than 480 representative exhibits made global, Asian, or China debuts — a record high . The value of these debuts lies not only in how new the technology is, but also in whether cutting-edge innovation can respond to real needs and move faster into practical use.
Among Bayer's nearly 30 debut exhibits, Sunharbo (asundexian tablets) — a newly approved, first-in-class medicine — became one of the most closely watched innovations. It was selected as one of the "Top 10 Breakthrough Technologies" in the report Powering the Future: Report on Cutting-Edge and Hard-Tech Exhibits at the 9th CIIE, and was featured on CCTV's "CIIE New Products Showcase" program, reflecting how quickly frontier scientific innovation is moving toward real-world application.
Additionally, Gadoquatrane Injection — a third-generation novel gadolinium-based contrast agent with a tetrameric structure — made its China debut, and the MEDRAD Mark 7 Arterion high-pressure injection system made its CIIE debut following localization.
The same translation of innovation into impact is under way in Consumer Health and Crop Science. At this CIIE, Bayer Consumer Health brought seven global debuts, addressing the increasingly diverse health needs of Chinese consumers across an array scenarios — including teen scalp care, babies' skin care, maternal and babies' health, and nutritional supplementation. In agriculture, Bayer Crop Science brought eight China debuts and six CIIE debuts, spanning its three core businesses of crop protection, corn seeds, and vegetable seeds. These innovations, developed to meet real needs in China, will move beyond the CIIE and into hospitals, pharmacies, and fields, creating value for patients, consumers, and growers.
